Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amneal PharmaceuticalsAMRX -0.11%59 EV-to-OCF is 43.05 as of Aug. 05, 2026, which is 147% above its 10-year median of 17.41. GuruFocus rates AMRX with a GF Score™ of 59/100 and a GF Value™ of $8.15 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Amneal Pharmaceuticals ranks worse than 86.41% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Amneal Pharmaceuticals's Enterprise Value is $8,643 Mil.
Amneal Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $201 Mil. Therefore, Amneal Pharmaceuticals's EV-to-OCF for today is 43.05.
The historical rank and industry rank for Amneal Pharmaceuticals's EV-to-OCF or its related term are showing as below:
AMRX'
s EV-to-OCF Range Over the Past 10 Years
Min: 6.9 Med: 17.41 Max: 2027.86
Current: 43.05
During the past 10 years, the highest EV-to-OCF of Amneal Pharmaceuticals was 2027.86. The lowest was 6.90. And the median was 17.41.
AMRX's EV-to-OCF is ranked worse than 86.41% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.825
vs AMRX: 43.05
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Amneal Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Amneal Pharmaceuticals's share price for today is $18.47.
Amneal Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.490.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amneal Pharmaceuticals EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Amneal Pharmaceuticals's EV-to-OCF falls into.
Amneal Pharmaceuticals's current Enterprise Value is $8,643 Mil.
Amneal Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $201 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amneal Pharmaceuticals (AMRX) has a EV-to-OCF of 43.05 as of Aug. 05, 2026. This is 147% above median its historical median of 17.41. Over the past decade, Amneal Pharmaceuticals' EV-to-OCF has ranged from 6.90 to 2,027.86. According to the industry distribution chart, Amneal Pharmaceuticals ranks #871 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 86.4%.
Is Amneal Pharmaceuticals' EV-to-OCF too high?
Amneal Pharmaceuticals' current EV-to-OCF of 43.05 is 147% above median its 10-year median of 17.41. Over the past 10 years, this metric has ranged from a low of 6.90 to a high of 2,027.86. The Drug Manufacturers industry median EV-to-OCF is 10.83. Amneal Pharmaceuticals' value of 43.05 is 297.7% above this industry median. Based on the distribution chart, Amneal Pharmaceuticals ranks #871 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Amneal Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' EV-to-OCF compare to HIMS and KNSA?
According to the Drug Manufacturers industry distribution chart, Amneal Pharmaceuticals ranks #871 out of 1008 companies for EV-to-OCF. This places Amneal Pharmaceuticals in the lower half of its industry. The industry median EV-to-OCF is 10.83. Amneal Pharmaceuticals' value of 43.05 is 297.7% above this benchmark. Historically, Amneal Pharmaceuticals' own EV-to-OCF has ranged from 6.90 to 2,027.86 over the past decade. While the company's 10-year median is 17.41 vs. the industry median of 10.83, Amneal Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.83, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amneal Pharmaceuticals's current EV-to-OCF of 43.05 is 297.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amneal Pharmaceuticals's current EV-to-OCF is 43.05, which is 147% above median its own 10-year median of 17.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $8.15, compared to a current price of $18.47 — trading 126.6% above its estimated fair value. The current EV-to-OCF is 43.05, which is 147% above median its 10-year median of 17.41 and 297.7% above the Drug Manufacturers industry median of 10.83. Amneal Pharmaceuticals' overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current EV-to-OCF is 43.05 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?
Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued.
The current stock price of $18.47 is trading 126.6% above its estimated GF Value™ of $8.15.
GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for AMRX:
EV-to-OCF: 43.05 (147% above median its 10-year median of 17.41)
GF Value™: $8.15 vs. price of $18.47 (126.6% above fair value)
Industry Position: 297.7% above the Drug Manufacturers median (#871 of 1008)
No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
59GF Score
Get the complete analysis for AMRX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMRX has been successfully added to your 
